|
 The 543-participant study assessed Sage's once-daily oral drug,
zuranolone, as a two-week course for depression episodes, after
which patients can return to work or their normal life.
The Cambridge, Massachusetts-based company has been developing
zuranolone with partner Biogen Inc. Biogen tied up with Sage in a
deal worth over $1.5 billion plus milestone payments in November to
co-develop drugs for depression and other neurological disorders.
Major Depressive Disorder, known more commonly as clinical
depression, affects over 16 million American adults every year, and
impedes patients' ability to carry out daily activities such as
work, school or social interactions.
There is a shortage of treatment options for the condition, which is
mainly treated with antidepressants such as Eli Lilly and Co's
Prozac and Pfizer Inc's Zoloft.
[to top of second column] |
 The drugs could take up to six
weeks to show effect and patients are typically
required to continue treatment for months after.
Zuranolone was generally well-tolerated in the
study and showed a safety profile consistent
with its previous clinical studies, Sage and
Biogen said in a joint statement.
(Reporting by Manojna Maddipatla in Bengaluru;
Editing by Arun Koyyur and Shinjini Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
